Tempest Therapeutics, Inc. Research And Development Expense

Quick Answer

Tempest Therapeutics, Inc. reported Research And Development Expense of $18.34 million for the year ending 2017.

  • Tempest Therapeutics, Inc. showed a decrease of -15.3% in Research And Development Expense from 2016 to 2017.
  • This data is from Tempest Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 15, 2018.
  • XBRL data for this metric is available from 2012 to 2017 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 6 years of available data (2012 to 2017), Tempest Therapeutics, Inc.'s Research And Development Expense has grown by 190.0%.
  • Historical annual values: Fiscal year 2017: $18.34 million | Fiscal year 2016: $21.64 million | Fiscal year 2015: $18.43 million | Fiscal year 2014: $21.78 million | Fiscal year 2013: $15.80 million | Fiscal year 2012: $6.32 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: